News

Cell Medica raises €21,7m
Enlarge image

BusinessUK

Cell Medica raises €21,7m

24.07.2012 - London-based biotech company Cell Medica, developing cell-based therapeutics, has closed a £17m (€21,7m) funding round.

The financing includes a significant contribution from a Texan state fund called The Cancer Prevention and Research Institute of Texas (CPRIT). Cell Medica is to begin new operations in Texas focused on cancer immunotherapy as a result of the funding, which will also finance ongoing immune reconstitution studies in Europe.

CPRIT is committing £9.7m (€12,4m) to Cell Medica, enabling it conduct US clinical development of its Cytorex EBV therapy to treat cancers associated with Epstein Barr virus. In Europe, the company's Cytovir technologies are being developed for the treatment of life-threatening viral infections in lymphoma and leukaemia patients who have undergone bone marrow transplants. The company hopes to launch its Cytovir therapy for cytomegalovirus in Europe next year following completion of two ongoing studies in the UK. Other investors include Invesco Perpetual (£4m or €5,1m) and Imperial Innovations (£3m, €3,8m). The Wellcome Trust also becomes a shareholder in the company through conversion of a loan security into equity. Cell Medica uses its technology to select, activate and expand T-cells to treat a range of indications. The firm has additionally appointed Thomas Hecht, a former transplant physician and previous senior executive in Amgen's European Operation, as chairman.

http://www.european-biotechnology-news.com/news/news/2012-03/cell-medica-raises-eur217m.html

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA98.35 CHF13.70%
  • EPIGENOMICS3.37 EUR6.65%
  • FORMYCON6.85 EUR1.48%

FLOP

  • MOLOGEN7.38 EUR-5.87%
  • EVOTEC3.74 EUR-5.08%
  • CYTOS0.25 CHF-3.85%

TOP

  • SANTHERA98.35 CHF53.7%
  • BB BIOTECH141.00 EUR6.3%
  • ADDEX3.98 CHF4.2%

FLOP

  • WILEX2.25 EUR-24.7%
  • MOLOGEN7.38 EUR-18.8%
  • 4SC1.22 EUR-15.9%

TOP

  • SANTHERA98.35 CHF4121.0%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR179.3%

FLOP

  • CYTOS0.25 CHF-93.6%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014